<i>PINCH‐2</i> presents functional copy number variation and suppresses migration of colon cancer cells by paracrine activity

Chan Hee Park(Jeonbuk National University), Hyun Cheol Chung(Yonsei University)

International Journal of Cancer

October 23, 2014

10.1002/ijc.29273

Cited by 14

Related Papers

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

|The Lancet|2010|7.3k

Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial

|The Lancet|2018|1.3k

Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort

|Journal of Clinical Oncology|2016|859

Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial

|The Lancet Oncology|2013|838

The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer

|Nature|2021|687